Status:
COMPLETED
Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Collaborating Sponsors:
Technical University of Munich
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess whether abciximab is associated with additional benefit in patients with AMI treated with PCI after high dose clopidogrel loading.
Detailed Description
The goal of all reperfusion therapies in acute myocardial infarction (AMI) is an effective restoration of coronary blood flow and the reduction of infarct size. Recently, the researchers were able to ...
Eligibility Criteria
Inclusion
- Patients presenting with ST-Elevation acute myocardial infarction within 24 hours from the onset of symptoms
Exclusion
- Age \>80 years
- Malignancies
- Cardiogenic shock
- Prolonged cardio-pulmonary resuscitation
- Increased risk of bleeding
- Relevant hematologic deviations (hemoglobin \<100 g/L or hematocrit \<34%, platelet count \<100 x 10\^9 /L or platelet count \>600 x 10\^9 /L)
- Known allergy to the study medication
- Pregnancy (present or suspected)
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00133250
Start Date
June 1 2003
End Date
March 1 2008
Last Update
March 16 2010
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Allgemeines Krankenhaus Wien
Vienna, Austria, 1090
2
Klinikum Garmisch-Partenkirchen
Garmisch-Partenkirchen, Germany, 82467
3
Deutsches Herzzentrum Muenchen
Munich, Germany, 80636
4
First Medizinische Klinik, Klinikum rechts der Isar
Munich, Germany, 81675